Vascular Endothelial Growth Factor and Programmed Death-1 Pathway Inhibitors in Renal Cell Carcinoma

Overview

Journal Cancer

Publisher Wiley

Specialty Oncology

Date 2019 Sep 19

PMID 31532565

Citations 20

Authors

Charlene M Mantia

David F Mcdermott

Affiliations

Soon will be listed here.

Abstract

Advanced renal cell carcinoma has historically carried a poor prognosis with very limited treatment options. However, in recent years, the treatment landscape has changed drastically, with many new therapeutic options and improved survival for patients. Novel treatments consist of molecularly targeted agents against the vascular endothelial growth factor (VEGF) pathway as well as the immune checkpoint inhibitors, which stimulate an antitumor immune response. Recent strategy has focused on the development of combination therapy with the use of VEGF inhibitors and immune checkpoint inhibitors in the first-line setting. As more treatments are approved and the options for therapy expand further, there is a growing need for predictive biomarkers to personalize treatment choices for individual patients. Prospective clinical trials comparing the sequencing of treatments are needed to help determine the best therapeutic approach.

Citing Articles

Growth of Renal Cancer Cell Lines Is Strongly Inhibited by Synergistic Activity of Low-Dosed Amygdalin and Sulforaphane.

Markowitsch S, Pham T, Rutz J, Chun F, Haferkamp A, Tsaur I Nutrients. 2024; 16(21).

PMID: 39519581 PMC: 11547972. DOI: 10.3390/nu16213750.

Lack of VEGFA/KDR Signaling in Conventional Renal Cell Carcinoma Explains the Low Efficacy of Target Therapy and Frequent Adverse Events.

Peterfi L, Yusenko M, Kovacs G, Beothe T Int J Mol Sci. 2024; 25(13).

PMID: 39000466 PMC: 11242259. DOI: 10.3390/ijms25137359.

Durable response to nivolumab rechallenge in a patient with metastatic clear cell renal cell carcinoma.

Fujiwara M, Shimada W, Yokoyama M, Koyanagi A, Shintaku H, Fukuda S IJU Case Rep. 2024; 7(4):293-296.

PMID: 38966764 PMC: 11221937. DOI: 10.1002/iju5.12727.

Acute kidney injury in cancer patients receiving anti-vascular endothelial growth factor monoclonal antibody vs. immune checkpoint inhibitors: a retrospective real-world study.

Zhu J, Ding X, Zhang J, Chen B, You X, Chen X BMC Cancer. 2024; 24(1):756.

PMID: 38914959 PMC: 11194933. DOI: 10.1186/s12885-024-12540-y.

Rationale for immune checkpoint inhibitors plus targeted therapy for advanced renal cell carcinoma.

Yang S, Yang X, Hou Z, Zhu L, Yao Z, Zhang Y Heliyon. 2024; 10(7):e29215.

PMID: 38623200 PMC: 11016731. DOI: 10.1016/j.heliyon.2024.e29215.

References

Motzer R, Hutson T, Glen H, Michaelson M, Molina A, Eisen T . Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015; 16(15):1473-1482. DOI: 10.1016/S1470-2045(15)00290-9. View

Inamura K . Renal Cell Tumors: Understanding Their Molecular Pathological Epidemiology and the 2016 WHO Classification. Int J Mol Sci. 2017; 18(10). PMC: 5666876. DOI: 10.3390/ijms18102195. View

Motzer R, Escudier B, Tomczak P, Hutson T, Michaelson M, Negrier S . Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol. 2013; 14(6):552-62. DOI: 10.1016/S1470-2045(13)70093-7. View

Choueiri T, Escudier B, Powles T, Mainwaring P, Rini B, Donskov F . Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373(19):1814-23. PMC: 5024539. DOI: 10.1056/NEJMoa1510016. View

Motzer R, Escudier B, Mcdermott D, George S, Hammers H, Srinivas S . Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373(19):1803-13. PMC: 5719487. DOI: 10.1056/NEJMoa1510665. View

Motzer R, Hutson T, Cella D, Reeves J, Hawkins R, Guo J . Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013; 369(8):722-31. DOI: 10.1056/NEJMoa1303989. View

Miao D, Margolis C, Gao W, Voss M, Li W, Martini D . Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018; 359(6377):801-806. PMC: 6035749. DOI: 10.1126/science.aan5951. View

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View

Dudani S, Graham J, Wells J, Bakouny Z, Pal S, Dizman N . First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium. Eur Urol. 2019; 76(6):861-867. PMC: 6858928. DOI: 10.1016/j.eururo.2019.07.048. View

10.

Sternberg C, Davis I, Mardiak J, Szczylik C, Lee E, Wagstaff J . Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010; 28(6):1061-8. DOI: 10.1200/JCO.2009.23.9764. View

11.

Hutson T, Lesovoy V, Al-Shukri S, Stus V, Lipatov O, Bair A . Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. Lancet Oncol. 2013; 14(13):1287-94. DOI: 10.1016/S1470-2045(13)70465-0. View

12.

Rini B, Campbell S, Escudier B . Renal cell carcinoma. Lancet. 2009; 373(9669):1119-32. DOI: 10.1016/S0140-6736(09)60229-4. View

13.

Kusmartsev S, Eruslanov E, Kubler H, Tseng T, Sakai Y, Su Z . Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma. J Immunol. 2008; 181(1):346-53. DOI: 10.4049/jimmunol.181.1.346. View

14.

Choueiri T, Halabi S, Sanford B, Hahn O, Michaelson M, Walsh M . Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. J Clin Oncol. 2017; 35(6):591-597. PMC: 5455807. DOI: 10.1200/JCO.2016.70.7398. View

15.

Choueiri T, Hessel C, Halabi S, Sanford B, Michaelson M, Hahn O . Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. Eur J Cancer. 2018; 94:115-125. PMC: 6057479. DOI: 10.1016/j.ejca.2018.02.012. View

16.

Hsieh J, Purdue M, Signoretti S, Swanton C, Albiges L, Schmidinger M . Renal cell carcinoma. Nat Rev Dis Primers. 2017; 3:17009. PMC: 5936048. DOI: 10.1038/nrdp.2017.9. View

17.

Fyfe G, Fisher R, Rosenberg S, Sznol M, Parkinson D, Louie A . Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995; 13(3):688-96. DOI: 10.1200/JCO.1995.13.3.688. View

18.

Rini B, Powles T, Atkins M, Escudier B, Mcdermott D, Suarez C . Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet. 2019; 393(10189):2404-2415. DOI: 10.1016/S0140-6736(19)30723-8. View

19.

Sharma S, Nanda S, Longo S . Anti-angiogenic therapy in renal cell carcinoma. Recent Pat Anticancer Drug Discov. 2009; 5(1):77-83. DOI: 10.2174/157489210789702181. View

20.

Upton M, Parker R, Youmans A, Mcdermott D, Atkins M . Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J Immunother. 2005; 28(5):488-95. DOI: 10.1097/01.cji.0000170357.14962.9b. View